• Fresh capital should enable Apium to focus more on the medical sector / Current investor unable to raise additional funds
• Manufacturer of machine tools with patented technology for processing high-performance thermoplastics into high-strength components / Faster treatment success thanks to customized implant solutions for patients
• Provisional insolvency administrator Holger Blümle of German law firm Schultze & Braun: "I believe Apium has great potential if we can find an investor to support the young company. As a result of the high costs of development work, Apium is unable to fully exploit its potential in market development and the further improvement of its products under the current ownership structure. The ongoing preliminary insolvency proceedings offer investors the opportunity to take over the company free of inherited burdens and lead it into the future."

Karlsruhe (Germany). Karlsruhe-based Apium Additive Technologies GmbH has resumed its search for investors. "We already successfully serve the industrial and medical markets worldwide with our existing 3D printers and would like to focus more on the medical sector. To this end, we want to qualify our latest product platform, the industrial 3D printer Apium P400, which we developed to market standard in recent years, for the medical market. We need fresh capital to enable us to take this step. This will allow us to reap the rewards of our development work over the past few months. However, our current investor is unable to provide any additional funds for this," explains Apium’s Managing Director Lars Pfotzer. "We have therefore decided to restructure our young company in insolvency proceedings and resume the search for investors."

The company Apium Additive Technologies sees itself as a manufacturer of machine tools. "Our patented technology is one of the few manufacturing processes on the market that is capable of processing high-performance thermoplastics in such a way that high-strength components are produced that are proven to be suitable for the manufacture of medical implants. Our customers are already successfully using our 3D printers to produce customized implant solutions according to medical specifications and on the basis of CT/MRI data, which can be implanted in patients and enable faster treatment success compared to conventional methods. At the same time, medical research institutes use our products to develop and test materials and components so that these can later be used in everyday clinical practice," says Managing Director Pfotzer.

Founded in 2016, the start-up Apium Additive Technologies now employs 15 people and recently generated annual sales of around one million euros. "I see great potential for Apium if we can find an investor to support the young company. As a result of the high costs of development work, Apium is unable to fully exploit its potential in market development and the further improvement of its products under the current ownership structure. The ongoing preliminary insolvency proceedings offer investors the opportunity to take over the company free from inherited burdens and to lead it into the future," says the preliminary insolvency administrator Holger Blümle from the Karlsruhe office of Germany-wide law firm Schultze & Braun, appointed by Karlsruhe Local Court.

Business operations at Apium Additive Technologies will continue without restrictions even after the insolvency application. "We aim at entering into negotiations with potential investors as soon as possible so that we can quickly release Apium from the proceedings," says the provisional insolvency administrator Holger Blümle. He has already received initial expressions of interest.